This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to
About the Federal Register
on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.
Notice
Enter a search term or FR citation e.g.
88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN
Choosing an item from
full text search results
will bring you to those results. Pressing enter in the search box
will also bring you to search results.
Choosing an item from
suggestions
will bring you directly to the content.
This table of contents is a navigational tool, processed from the
headings within the legal text of Federal Register documents.
This repetition of headings to form internal navigation links
has no substantive legal effect.
Comments are no longer being accepted.
See DATES for details.
Regulations.gov Data
Enhanced Content - Regulations.gov Data
FederalRegister.gov retrieves relevant information about this document
from Regulations.gov to provide users with additional context. This
information is not part of the official Federal Register document.
Federal Registers, Written and Electronic Submissions that does not include a Docket Number or ID_2026
Document page views are updated periodically throughout the day and are
cumulative counts for this document. Counts are subject to sampling,
reprocessing and revision (up or down) throughout the day.
Page views
5,454
as of
10/13/2026 at 2:15 am EDT
Other Formats
Enhanced Content - Other Formats
This document is also available in the following formats:
This PDF is FR Doc. 2026-15297 as it appeared on Public Inspection on
07/28/2026 at 11:15 am.
It was viewed
376
times while on Public Inspection.
If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507.
Learn more here.
Published Document: 2026-15297 (91 FR 47835)
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration's (FDA) plans to centralize and enhance key functions across the agency. These changes will reduce redundancies, improve efficiency, and advance alignment to better serve the American public.
FOR FURTHER INFORMATION CONTACT:
Eric Stone, Acting Associate Director for Enterprise Solutions, Office of Operations, 10903 New Hampshire Avenue, Silver Spring, MD 20993.
I. Introduction
Part D, Chapter D-B, (Food and Drug Administration), the Statement of Organization, Functions and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, 60 FR 56606, November 9, 1995, 64 FR 36361, July 6, 1999, 72 FR 50112, August 30, 2007, 74 FR 41713, August
( printed page 47836)
18, 2009, 76 FR 45270, July 28, 2011, 84 FR 22854, May 20, 2019, and 89 FR 105052, December 26, 2024) is revised to reflect the Food and Drug Administration's plans to centralize and enhance functions across the agency.
DCA. ORGANIZATION. The Food and Drug Administration's Office of the Commissioner and includes the following organizational units:
OFFICE OF THE COMMISSIONER (DCA)
OFFICE OF THE CHIEF COUNSEL (DCAA)
OFFICE OF EXECUTIVE SECRETARIAT (DCAB)
OFFICE OF THE COUNSELOR TO THE COMMISSIONER (DCAC)
OFFICE OF NATIONAL HEALTH SECURITY (DCAH)
PUBLIC HEALTH PREPAREDNESS AND RESPONSE STAFF (DCAH1)
SUPPLY CHAIN RESILIENCY STAFF (DCAH2)
DCB. ORGANIZATION. The Center for Biologics, Evaluation, and Research includes the following organizational units:
CENTER FOR BIOLOGICS, EVALUATION AND RESEARCH (DCB)
OFFICE OF THE CENTER DIRECTOR (DCBA)
REGULATORY PROGRAMS, OPERATIONS, AND COMMUNICATIONS STAFF (DCBA2)
REGULATIONS AND POLICY STAFF (DCBA3)
REGULATORY DATA, STANDARDS, AND REPORTING STAFF (DCBA4)
POLICY STAFF (DCBA7)
SCIENCE AND SAFETY STAFF (DCBA8)
VETERINARY SERVICES STAFF (DCBA9)
OFFICE OF COMPLIANCE AND BIOLOGICS QUALITY (DCBC)
DIVISION OF CASE MANAGEMENT (DCBCA)
BLOOD AND TISSUE COMPLIANCE BRANCH (DCBCA1)
ADVERTISING AND PROMOTIONAL LABELING BRANCH (DCBCA2)
BIOLOGICAL DRUG AND DEVICE COMPLIANCE BRANCH 1 (DCBCA3)
BIOLOGICAL DRUG AND DEVICE COMPLIANCE BRANCH 2 (DCBCA4)
DIVISION OF INSPECTIONS AND SURVEILLANCE (DCBCB)
PROGRAM SURVEILLANCE BRANCH (DCBCB1)
BIORESEARCH MONITORING BRANCH (DCBCB2)
DIVISION OF MANUFACTURING AND PRODUCT QUALITY (DCBCC)
PRODUCT RELEASE BRANCH (DCBCC1)
MANUFACTURING REVIEW BRANCH 1 (DCBCC2)
MANUFACTURING REVIEW BRANCH 2 (DCBCC3)
APPLICATIONS REVIEW BRANCH (DCBCC4)
MANUFACTURING REVIEW BRANCH 3 (DCBCC5)
DIVISION OF BIOLOGICAL STANDARDS AND QUALITY CONTROL (DCBCD)
QUALITY ASSURANCE BRANCH (DCBCD2)
LABORATORY OF MICROBIOLOGY, IN-VIVO TESTING AND STANDARDS BRANCH (DCBCD3)
LABORATORY OF ANALYTICAL CHEMISTRY BRANCH (DCBCD4)
LABORATORY OF BIOCHEMISTRY, VIROLOGY, AND IMMUNOCHEMISTRY BRANCH (DCBCD5)
LABORATORY OF BLOOD RELATED PRODUCTS BRANCH (DCBCD6)
OFFICE OF BIOSTATISTICS AND PHARMACOVIGILANCE (DCBD)
CBER SURVEILLANCE PROGRAM STAFF (DCBD1)
DIVISION OF BIOSTATISTICS (DCBDA)
VACCINE EVALUATION BRANCH (DCBDA1)
THERAPEUTICS EVALUATION BRANCH 1 (DCBDA2)
DEVICE AND NON-CLINICAL EVALUATION BRANCH (DCBDA3)
THERAPEUTICS EVALUATION BRANCH 2 (DCBDA4)
DIVISION OF PHARMACOVIGILANCE (DCBDB)
PHARMACOVIGILANCE BRANCH 1 (DCBDB1)
PHARMACOVIGILANCE BRANCH 2 (DCBDB2)
PHARMACOVIGILANCE BRANCH 3 (DCBDB3)
DIVISION OF ANALYTICS AND BENEFIT-RISK ASSESSMENT (DCBDC)
BENEFIT-RISK ASSESSMENT BRANCH (DCBDC1)
ANALYTICS AND REAL-WORLD EVIDENCE BRANCH (DCBDC2)
OFFICE OF BLOOD RESEARCH AND REVIEW (DCBE)
REGULATORY PROJECT MANAGEMENT STAFF (DCBE2)
DIVISION OF EMERGING AND TRANSFUSION TRANSMITTED DISEASES (DCBEA)
LABORATORY OF MOLECULAR VIROLOGY (DCBEA1)
LABORATORY OF EMERGING PATHOGENS (DCBEA2)
PRODUCT REVIEW BRANCH (DCBEA4)
DIVISION OF BLOOD COMPONENTS AND DEVICES (DCBEB)
DEVICES REVIEW BRANCH (DCBEB2)
BLOOD AND PLASMA BRANCH (DCBEB6)
LABORATORY OF CELLULAR HEMATOLOGY (DCBEB7)
LABORATORY OF BIOCHEMISTRY AND VASCULAR BIOLOGY (DCBEB8)
OFFICE OF VACCINES RESEARCH AND REVIEW (DCBF)
DIVISION OF BACTERIAL PARASITIC AND ALLERGENIC PRODUCTS (DCBFA)
LABORATORY OF IMMUNOBIOCHEMISTRY (DCBFA1)
LABORATORY OF RESPIRATORY AND SPECIAL PATHOGENS (DCBFA2)
LABORATORY OF BACTERIAL PLOYSACCHARIDES (DCBFA3)
LABORATORY OF MUCOSAL PATHOGENS AND CELLULAR IMMUNOLOGY (DCBFA4)
DIVISION OF VIRAL PRODUCTS (DCBFB)
LABORATORY OF PEDIATRIC AND RESPIRATORY VIRAL DISEASES (DCBFB1)
LABORATORY OF HEPATITIS VIRUSES (DCBFB2)
LABORATORY OF RETORVIRUSES (DCBFB3)
LABORATORY OF DNA VIRUSES (DCBFB4)
LABORATORY OF VECTOR BORNE DISEASES (DCBFB5)
LABORATORY OF METHOD DEVELOPMENT (DCBFB6)
LABORATORY OF IMMUNOREGULATIONS (DCBFB7)
DIVISION OF REVIEW MANAGEMENT AND REGULATORY REVIEW (DCBFD)
REGULATORY REVIEW BRANCH 1 (DCBFD1)
REGULATORY REVIEW BRANCH 2 (DCBFD2)
REGULATORY REVIEW BRANCH 3 (DCBFD3)
REVIEW MANAGEMENT SUPPORT BRANCH (DCBFD4)
DIVISION OF CLINICAL AND TOXICOLOGY REVIEW (DCBFE)
CLINICAL REVIEW BRANCH 1 (DCBFE1)
CLINICAL REVIEW BRANCH 2 (DCBFE2)
CLINICAL REVIEW BRANCH 3 (DCBFE3)
TOXICOLOGY STAFF (DCBFE4)
OFFICE OF THERAPEUTIC PRODUCTS (DCBG)
POLCY AND SPECIAL PROJECTS STAFF (DCBG2)
OFFICE OF GENE THERAPY CMC (DCBGF)
DIVISION OF GENE THERAPY I (DCBGFA)
GENE THERAPY BRANCH 1 (DCBGFA1)
GENE THERAPY BRANCH 2 (DCBGFA2)
GENE THERAPY BRANCH 3 (DCBGFA3)
DIVISION OF GENE THERAPY II (DCBGFB)
GENE TRANSFER AND IMMUNOGENICITY BRANCH (DCBGFB1)
GENE THERAPY BRANCH 4 (DCBGFB2)
GENE THERAPY BRANCH 5 (DCBGFB3)
OFFICE OF CELLULAR THERPY AND HUMAN TISSUE CMC (DCBGG)
DIVISION OF CELL THERAPY I (DCBGGA)
CELL THERAPY BRANCH 1 (DCBGGA1)
CELL THERAPY BRANCH 2 (DCBGGA2)
CELLULAR AND TISSUE THERAPY BRANCH (DCBGGA3)
DIVISION OF CELL THERAPY II (DCBGGB)
TISSUE ENGINEERING BRANCH 1 (DCBGGB1)
TISSUE ENGINEERING BRANCH 2 (DCBGGB2)
TUMOR VACCINE AND BIOTECHNOLOGY BRANCH (DCBGGB3)
DIVISION OF HUMAN TISSUES (DCBGGC)
HUMAN TISSUES AND REPRODUCTION STAFF (DCBGGC1)
OFFICE OF PLASMA PROTEIN THERAPEUTICS CMC (DCBGH)
DIVISION OF HEMOSTASIS (DCBGHA)
HEMOSTASIS BRANCH 1 (DCBGHA1)
HEMOSTASIS BRANCH 2 (DCBGHA2)
DIVISION OF PLASMA DERIVATIVES (DCBGHB)
PLASMA DERIVATIVES BRANCH 1 (DCBGHB1)
PLASMA DERIVATIVES BRANCH 2 (DCBGHB2)
OFFICE OF CLINICAL EVALUATION (DCBGI)
DIVISION OF CLINICAL EVALUATION GENERAL MEDICINE (DCBGIA)
( printed page 47837)
GENERAL MEDICINE BRANCH 1 (DCBGIA1)
GENERAL MEDICINE BRANCH 2 (DCBGIA2)
GENERAL MEDICINE BRANCH 3 (DCBGIA3)
GENERAL MEDICINE BRANCH 4 (DCBGIA4)
DIVISION OF CLINICAL EVALUATION ONCOLOGY (DCBGIB)
ONCOLOGY BRANCH 1 (DCBGIB1)
ONCOLOGY BRANCH 2 (DCBGIB2)
DIVISION OF CLINICAL EVALUATION HEMATOLOGY (DCBGIC)
BENIGN HEMATOLOGY BRANCH (DCBGIC1)
MALIGNANT HEMATOLOGY BRANCH (DCBGIC2)
OFFICE OF PHARMACOLOGY TOXICOLOGY (DCBGJ)
DIVISION OF PHARMACOLOGY TOXICOLOGY I (DCBGJA)
PHARMACOLOGY TOXICOLOGY BRANCH 1 (DCBGJA1)
PHARMACOLOGY TOXICOLOGY BRANCH 3 (DCBGJA2)
DIVISION OF PHARMACOLOGY TOXICOLOGY II (DCBGJB)
PHARMACOLOGY TOXICOLOGY BRANCH 2 (DCBGJB1)
PHARMACOLOGY TOXICOLOGY BRANCH 4 (DCBGJB2)
OFFICE OF REVIEW MANAGEMENT AND REGULATORY REVIEW (DCBGK)
DIVISION OF REVIEW MANAGEMENT AND REGULATORY REVIEW I (DCBGKA)
REGULATORY REVIEW BRANCH 1 (DCBGKA1)
REVIEW MANAGEMENT SUPPORT BRANCH 1 (DCBGKA2)
DIVISION OF REVIEW MANAGEMENT AND REGULATORY REVIEW II (DCBGKB)
REGULATORY REVIEW BRANCH 2 (DCBGKB1)
REVIEW MANAGEMENT SUPPORT BRANCH 2 (DCBGKB2)
DCC. ORGANIZATION. The Center for Devices and Radiological Health includes the following organizational units:
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (DCC)
OFFICE OF THE CENTER DIRECTOR (DCCA)
QUALITY MANAGEMENT STAFF (DCCA1)
OFFICE OF STRATEGIC PARTNERSHIP AND TECHNOLOGY INNOVATION (DCCC)
OFFICE OF READINESS AND RESPONSE (DCCCD)
DIVISION OF ALL HAZARD PREPAREDNESS AND RESPONSE (DCCCDA)
DIVISION OF STANDARDS AND CONFORMITY ASSESSMENT (DCCCDB)
DIVISION OF MEDICAL DEVICE CYBERSECURITY (DCCCDC)
OFFICE OF INNOVATIVE DEVELOPMENT (DCCCE)
DIVISION OF PATIENT-CENTERED DEVELOPMENT (DCCCEA)
DIVISION OF PARTNERSHIPS AND INNOVATION (DCCCEC)
DIGITAL HEALTH CENTER OF EXCELLENCE (DCCCF)
DIVISION OF DIGITAL HEALTH POLICY (DCCCFA)
DIVISION OF DIGITAL HEALTH TECHNOLOGY ASSESSMENT (DCCCFB)
DIVISION OF DIGITAL HEALTH OUTREACH (DCCCFC)
OFFICE OF SUPPLY CHAIN RESILIENCE (DCCCH)
DIVISION OF SHORTAGE ASSESSMENT AND PRODUCT AUTHENTICATION (DCCCHA)
DIVISION OF PREVENTION, INNOVATION, AND RESILIENCE (DCCCHB)
OFFICE OF SCIENCE AND ENGINEERING LABORATORIES (DCCD)
DIVISION OF BIOMEDICAL PHYSICS (DCCDA)
DIVISION OF IMAGING, DIAGNOSTICS, AND SOFTWARE RELIABILITY (DCCDB)
DIVISION OF APPLIED MECHANICS (DCCDC)
DIVISION OF ADMINISTRATIVE AND LABORATORY SUPPORT (DCCDD)
DIVISION OF BIOLOGY, CHEMISTRY, AND MATERIALS SCIENCE (DCCDE)
OFFICE OF PRODUCT EVALUATION AND QUALITY (DCCF)
QUALITY AND ANALYTICS STAFF (DCCF1)
CLINICAL AND SCIENTIFIC POLICY STAFF (DCCF2)
STRATEGIC INITIATIVES STAFF (DCCF3)
REGULATIONS POLICY AND GUIDANCE STAFF (DCCF4)
OFFICE OF REGULATORY PROGRAMS (DCCFA)
DIVISION OF REGULATORY PROGRAMS I (DCCFAA)
DIVISION OF REGULATORY PROGRAMS II (DCCFAB)
DIVISION OF REGULATORY PROGRAMS III (DCCFAC)
DIVISION OF REGULATORY PROGRAMS IV (DCCFAD)
OFFICE OF CLINICAL EVIDENCE AND ANALYSIS (DCCFB)
DIVISION OF CLINICAL EVIDENCE AND ANALYSIS I (DCCFBA)
DIVISION OF CLINICAL EVIDENCE AND ANALYSIS II (DCCFBB)
DIVISION OF CLINICAL EVIDENCE AND ANALYSIS III (DCCFBC)
DIVISION OF CLINICAL EVIDENCE AND ANALYSIS IV (DCCFBD)
DIVISION OF CLINICAL EVIDENCE AND ANALYSIS V (DCCFBE)
OFFICE OF HEALTH TECHNOLOGY I (DCCFC)
DIVISION OF HEALTH TECHNOLOGY I A (DCCFCA)
DIVISION OF HEALTH TECHNOLOGY I B (DCCFCB)
DIVISION OF HEALTH TECHNOLOGY I C (DCCFCC)
OFFICE OF HEALTH TECHNOLOGY II (DCCFD)
DIVISION OF HEALTH TECHNOLOGY II A (DCCFDA)
DIVISION OF HEALTH TECHNOLOGY II B (DCCFDB)
DIVISION OF HEALTH TECHNOLOGY II C (DCCFDC)
OFFICE OF HEALTH TECHNOLOGY III (DCCFE)
DIVISION OF HEALTH TECHNOLOGY III A (DCCFEA)
DIVISION OF HEALTH TECHNOLOGY III B (DCCFEB)
DIVISION OF HEALTH TECHNOLOGY III C (DCCFEC)
OFFICE OF HEALTH TECHNOLOGY IV (DCCFF)
DIVISION OF HEALTH TECHNOLOGY IV A (DCCFFA)
DIVISION OF HEALTH TECHNOLOGY IV B (DCCFFB)
DIVISION OF HEALTH TECHNOLOGY IV C (DCCFFC)
OFFICE OF HEALTH TECHNOLOGY V (DCCFG)
DIVISION OF HEALTH TECHNOLOGY V A (DCCFGA)
DIVISION OF HEALTH TECHNOLOGY V B (DCCFGB)
OFFICE OF HEALTH TECHNOLOGY VI (DCCFH)
DIVISION OF HEALTH TECHNOLOGY VI A (DCCFHA)
DIVISION OF HEALTH TECHNOLOGY VI B (DCCFHB)
DIVISION OF HEALTH TECHNOLOGY VI C (DCCFHC)
OFFICE OF HEALTH TECHNOLOGY VII (DCCFI)
DIVISION OF CHEMISTRY AND TOXICOLOGY DEVICES (DCCFIA)
CHEMISTRY BRANCH (DCCFIA1)
DIABETES BRANCH (DCCFIA2)
TOXICOLOGY BRANCH (DCCFIA3)
CARDIO-RENAL DIAGNOSTICS BRANCH (DCCFIA4)
DIVISON OF IMMUNOLOGY AND HEMATOLOGY DEVICES (DCCFIB)
HEMATOLOGY BRANCH (DCCFIB1)
IMMUNOLOGY AND FLOW CYTOMETRY BRANCH (DCCFIB2)
DIVISION OF MICROBIOLOGY DEVICES (DCCFIC)
VIRAL RESPIRATORY AND HUMAN PAPILLOMA VIRUS BRANCH (DCCFIC1)
GENERAL VIRAL AND HUMAN HEPATITIS BRANCH (DCCFIC2)
GENERAL BACTERIAL AND ANTIMICROBIAL SUSCEPTIBILITY BRANCH (DCCFIC3)
BACTERIAL RESPIRATORY AND MEDICAL COUNTERMEASURES BRANCH (DCCFIC4)
DIVISION OF PROGRAM OPERATIONS AND MANAGEMENT (DCCFIE)
DIVISION OF MOLECULAR GENETICS AND PATHOLOGY (DCCFIG)
MOLECULAR PATHOLOGY AND CYTOLOGY BRANCH (DCCFIG1)
MOLECULAR GENETICS BRANCH (DCCFIG2)
OFFICE OF HEALTH TECHNOLOGY VIII (DCCFJ)
DIVISION OF HEALTH TECHNOLOGY VIII A (DCCFJA)
DIVISION OF HEALTH TECHNOLOGY VIII B (DCCFJB)
DIVISION OF HEALTH TECHNOLOGY VIII C (DCCFJC)
OFFICE OF POLICY (DCCG)
OFFICE OF INDUSTRY AND CONSUMER EDUCATION (DCCH)
( printed page 47838)
DCD. ORGANIZATION. The Center for Drug Evaluation and Research includes the following organizational units:
CENTER FOR DRUG EVALUATION AND RESEARCH (DCD)
OFFICE OF THE CENTER DIRECTOR (DCDA)
CONTROLLED SUBSTANCE STAFF (DCDA1)
COUNTER-TERRORISM AND EMERGENCY COORDINATION STAFF (DCDA3)
DRUG SHORTAGE STAFF (DCDA4)
OFFICE OF REGULATORY REVIEW (DCDB)
DIVISION OF REGULATORY REVIEW I (DCDBA)
DIVISION OF REGULATORY REVIEW II (DCDBB)
DIVISION OF REGULATORY REVIEW III (DCDBD)
DIVISION OF REGULATORY REVIEW IV (DCDBE)
OFFICE OF SURVEILLANCE AND EPIDEMIOLOGY (DCDE)
REGULATORY SCIENCE STAFF (DCDE1)
REGULATORY AFFAIRS STAFF (DCDE2)
PROJECT MANAGEMENT STAFF (DCDE4)
OFFICE OF MEDICATION ERROR PREVENTION AND RISK MANAGEMENT (DCDEA)
DIVISION OF MEDICATION ERROR PREVENTION AND ANALYSIS I (DCDEAA)
DIVISION OF RISK MANAGEMENT (DCDEAB)
DIVISION OF MEDICATION ERROR PREVENTION AND ANALYSIS II (DCDEAC)
DIVISION OF MITIGATION ASSESSMENT AND MEDICATION ERROR SURVEILLANCE (DCDEAD)
OFFICE OF PHARMACOVIGILANCE AND EPIDEMIOLOGY (DCDEB)
DIVISION OF EPIDEMIOLOGY I (DCDEBA)
DIVISION OF EPIDEMIOLOGY II (DCDEBB)
DIVISION OF PHARMACOVIGILANCE I (DCDEBC)
DIVISION OF PHARMACOVIGILANCE II (DCDEBD)
OFFICE OF COMPLIANCE (DCDF)
OFFICE OF MANUFACTURING QUALITY (DCDFA)
REGULATORY COMPLIANCE AND ANALYSIS STAFF (DCDFA2)
DIVISION OF DRUG QUALITY I (DCDFAA)
DIVISION OF DRUG QUALITY II (DCDFAB)
DIVISION OF DRUG QUALITY III (DCDFAD)
OFFICE OF UNAPPROVED DRUGS AND LABELING COMPLIANCE (DCDFB)
DIVISION OF UNAPPROVED DRUGS AND LABELING (DCDFBB)
FRAUD DRUGS BRANCH (DCDFBB2)
PRESCRIPTION DRUGS BRANCH (DCDFBB3)
DIVISION OF LABELING, REGISTRATION, AND UNAPPROVED DRUGS (DCDFBC)
OVER THE COUNTER DRUGS BRANCH (DCDFBC1)
DRUG REGISTRATION AND LISTING BRANCH (DCDFBC2)
OFFICE OF SCIENTIFIC INVESTIGATIONS (DCDFC)
REGULATORY COMPLIANCE STAFF (DCDFC1)
DIVISION OF GOOD CLINICAL PRACTICE COMPLIANCE (DCDFCA)
GOOD CLINICAL PRACTICE ENFORCEMENT BRANCH (DCDFCA1)
GOOD CLINICAL PRACTICE ASSESSMENT BRANCH (DCDFCA2)
DIVISION OF SAFETY COMPLIANCE (DCDFCB)
DIVISION OF ENFORCEMENT AND POSTMARKET SAFETY (DCDFCC)
COMPLIANCE ENFORCEMENT BRANCH (DCDFCC1)
POSTMARKETING SAFETY BRANCH (DCDFCC2)
DIVISION OF CLINICAL COMPLIANCE EVALUATION (DCDFCD)
GOOD CLINICAL PRACTICE ENFORCEMENT BRANCH (DCDFCD1)
GOOD CLINICAL PRACTICE ASSESSMENT BRANCH (DCDFCD2)
OFFICE OF DRUG SECURITY INTEGRITY AND RESPONSE (DCDFD)
DIVISION OF GLOBAL DRUG DISTRIBUTION (DCDFDA)
IMPORTS COMPLIANCE BRANCH (DCDFDA3)
EXPORTS COMPLIANCE BRANCH (DCDFDA4)
DIVISION OF SUPPLY CHAIN INTEGRITY (DCDFDB)
INCIDENTS, RECALLS, AND SHORTAGES BRANCH (DCDFDB3)
SUPPLY CHAIN SECURITY BRANCH (DCDFDB4)
OFFICE OF PROGRAM AND REGULATORY OPERATIONS (DCDFE)
PROGRAM AND REGULATORY OPERATIONS STAFF 1 (DCDFE1)
PROGRAM AND REGULATORY OPERATIONS STAFF 2 (DCDFE2)
PROGRAM AND REGULATORY OPERATIONS STAFF 3 (DCDFE4)
OFFICE OF COMPOUNDING QUALITY AND COMPLIANCE (DCDFF)
DIVISION OF COMPOUNDING I (DCDFFA)
COMPOUNDING BRANCH 1 (DCDFFA1)
COMPOUNDING BRANCH 2 (DCDFFA2)
COMPOUNDING BRANCH 3 (DCDFFA3)
DIVISION OF COMPOUNDING II (DCDFFB)
COMPOUNDING BRANCH 4 (DCDFFB2)
COMPOUNDING BRANCH 5 (DCDFFB3)
COMPOUNDING BRANCH 6 (DCDFFB4)
DIVISION OF COMPOUNDING III (DCDFFC)
COMPOUNDING BRANCH 7 (DCDFFC3)
COMPOUNDING BRANCH 8 (DCDFFC4)
OFFICE OF NEW DRUGS (DCDG)
PROGRAM MANAGEMENT ANALYSIS STAFF (DCDG1)
OFFICE OF NEUROSCIENCE (DCDGA)
DIVISION OF NEUROLOGY I (DCDGAB)
DIVISION OF NEUROLOGY II (DCDGAC)
DIVISION OF PSYCHIATRY (DCDGAD)
DIVISION OF ANESTHESIOLOGY, ADDICTION MEDICINE AND PAIN MEDICINE (DCDGAE)
DIVISION OF PHARMACOLOGY TOXICOLOGY FOR NEUROSCIENCE (DCDGAF)
OFFICE OF CARDIOLOGY, HEMATOLOGY, ENDOCRINOLOGY, AND NEPHROLOGY (DCDGB)
DIVISION OF DIABETES, LIPID DISORDERS, AND OBESITY (DCDGBA)
DIVISION OF GENERAL ENDOCRINOLOGY (DCDGBB)
DIVISION OF CARDIOLOGY AND NEPHROLOGY (DCDGBD)
DIVISION OF NON-MALIGNANT HEMATOLOGY (DCDGBE)
DIVISION OF PHARMACOLOGY TOXICOLOGY FOR CARDIOLOGY, HEMATOLOGY ENDOCRINOLOGY, AND NEPHROLOGY (DCDGBF)
OFFICE OF IMMUNOLOGY AND INFLAMMATION (DCDGC)
DIVISION OF GASTROENTEROLOGY (DCDGCA)
DIVISION OF DERMATOLOGY AND DENTISTRY (DCDGCC)
DIVISION OF RHEUMATOLOGY AND TRANSPLANT MEDICINE (DCDGCD)
DIVISION OF PULMONARY, ALLERGY AND CRITICAL CARE (DCDGCE)
DIVISION OF HEPATOLOGY AND NUTRITION (DCDGCF)
DIVISION OF PHARMACOLOGY TOXICOLOGY FOR IMMUNOLOGY AND INFLAMMATION (DCDGCG)
OFFICE OF INFECTIOUS DISEASES (DCDGD)
DIVISION OF ANTI-INFECTIVES (DCDGDA)
DIVISION OF ANTIVIRALS (DCDGDB)
DIVISION OF PHARMACOLOGY TOXICOLOGY FOR INFECTIOUS DISEASES (DCDGDC)
OFFICE OF RARE DISEASES, PEDIATRICS, UROLOGY AND REPRODUCTIVE MEDICINE (DCDGE)
DIVISION OF PEDIATRICS AND MATERNAL HEALTH (DCDGEC)
DIVISION OF PHARMACOLOGY TOXICOLOGY FOR RARE DISEASES, PEDIATRICS, UROLOGY AND REPRODUCTIVE MEDICINE (DCDGED)
DIVISION OF RARE DISEASES AND MEDICAL GENETICS (DCDGEE)
DIVISION OF UROLOGY, OBSTETRICS AND GYNECOLOGY (DCDGEF)
OFFICE OF ONCOLOGIC DISEASES (DCDGF)
DIVISION OF ONCOLOGY I (DCDGFA)
DIVISION OF HEMATOLOGIC MALIGNANCIES I (DCDGFB)
DIVISION OF ONCOLOGY II (DCDGFC)
DIVISION OF HEMATOLOGY ONCOLOGY TOXICOLOGY (DCDGFD)
DIVISION OF ONCOLOGY III (DCDGFF)
DIVISION OF HEMATOLOGIC MALIGNANACIES II (DCDGFG)
OFFICE OF THERAPEUTIC BIOLOGICS AND BIOSIMILARS (DCDGG)
OFFICE OF MEDICAL DEVICE AND RADIOLOGICAL HEALTH INSPECTORATE (DCSM)
DIVISION OF MAMMOGRAPHY AND RADIOLOGICAL HEALTH INSPECTORATE (DCSMA)
MAMMOGRAPHY OPERATIONS BRANCH 1 (DCSMA1)
MAMMOGRAPHY OPERATIONS BRANCH 2 (DCSMA2)
DIVISION OF MEDICAL DEVICE AND RADIOLOGICAL HEALTH INSPECTORATE I (DCSMB)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 1 (DCSMB1)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 2 (DCSMB2)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 3 (DCSMB3)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 4 (DCSMB4)
DIVISION OF MEDICAL DEVICE AND RADIOLOGICAL HEALTH INSPECTORATE II (DCSMC)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 1 (DCSMC1)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 2 (DCSMC2)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 3 (DCSMC3)
( printed page 47848)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 4 (DCSMC4)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 5 (DCSMC5)
DIVISION OF MEDICAL DEVICE AND RADIOLOGICAL HEALTH INSPECTORATE III (DCSMD)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 1 (DCSMD1)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 2 (DCSMD2)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 3 (DCSMD3)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 4 (DCSMD4)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 5 (DCSMD5)
DIVISION OF MEDICAL DEVICE AND RADIOLOGICAL HEALTH GLOBAL OPERATIONS (DCSME)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH FOREIGN OPERATIONS BRANCH (DCSME1)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH OPERATIONS BRANCH (DCSME2)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH RISK MITIGATION AND RESPONSE BRANCH (DCSME3)
DIVISION OF MEDICAL DEVICE AND RADIOLOGICAL HEALTH INSPECTORATE IV (DCSMF)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 1 (DCSMF1)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 2 (DCSMF2)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 3 (DCSMF3)
MEDICAL DEVICE AND RADIOLOGICAL HEALTH INVESTIGATIONS BRANCH 4 (DCSMF4)
DCT. ORGANIZATION. The Office of Health Advancement includes the following organizational units:
OFFICE OF HEALTH ADVANCEMENT (DCT)
OFFICE OF CLINICAL POLICY (DCTA)
OFFICE OF COMBINATION PRODUCTS (DCTB)
OFFICE OF ORPHAN PRODUCTS DEVELOPMENT (DCTC)
OFFICE OF PEDIATRIC THERAPEUTICS (DCTD)
OFFICE OF MINORITY HEALTH (DCTE)
OFFICE OF WOMEN'S HEALTH (DCTF)
DCU. ORGANIZATION. The Office of Mission Information Technology Services includes the following organizational units:
OFFICE OF MISSION INFORMATION TECHNOLOGY SERVICES (DCU)
OFFICE OF INFORMATION SECURITY (DCUA)
DIVISION OF CYBERSECURITY AND INFRASTRUCTURE OPERATIONS (DCUAA)
DIVISION OF RISK MANAGEMENT AND COMPLIANCE (DCUAB)
DIVISION OF COUNTERINTELLIGENCE AND INSIDER THREAT (DCUAC)
DIVISION OF CYBERSECURITY CAPABILITIES AND INTEGRATION (DCUAD)
DIVISION OF CYBERSECURITY PROGRAM (DCUAE)
OFFICE OF DATA PLATFORM ENGINEERING (DCUB)
DIVISION OF GATEWAY ENGINEERING (DCUBA)
DIVISION OF DATA PLATFORM ENGINEERING (DCUBB)
DIVISION OF PUBLISHING TECHNOLOGY PLATFORM ENGINEERING (DCUBC)
OFFICE OF BUSINESS APPLICATION SOLUTION (DCUC)
DIVISION OF REGULATORY SCIENCE APPLICATION SOLUTION (DCUCA)
DIVISION OF SAFETY AND QUALITY APPLICATION SOLUTION (DCUCB)
DIVISION OF INSPECTION AND COMPLIANCE APPLICATION SOLUTION (DCUCC)
OFFICE OF INFORMATION TECHNOLOGY OPERATIONS (DCUD)
DIVISION OF BUSINESS PARTNERSHIP AND SUPPORT (DCUDA)
DIVISION OF INFRASTRUCTURE OPERATIONS (DCUDB)
DIVISION OF INFORMATION TECHNOLOGY ARCHITECTURE AND INNOVATION (DCUDC)
DIVISION OF CENTER INFORMATION TECHNOLOGY LIAISON SERVICES (DCUDD)
DIVISION OF APPLICATION SUPPORT AND TRAINING (DCUDE)
OFFICE OF INFORMATION TECHNOLOGY PORTFOLIO AND PROGRAM MANAGEMENT (DCUE)
CONTRACT AND PROGRAM MANAGEMENT STAFF (DCUE1)
VENDOR MANAGEMENT STAFF (DCUE2)
DCV. ORGANIZATION. The Office of Public Affairs includes the following organizational units:
OFFICE OF PUBLIC AFFAIRS (DCV)
PUBLIC AFFAIRS COORDINATION STAFF (DCV1)
PRESS RELATIONS STAFF (DCV2)
OFFICE OF DIGITIAL EXPERIENCE AND STRATEGY (DCVA)
DIVISION OF CONTENT MANAGEMENT AND STRATEGY (DCVAA)
CONTENT MANAGEMENT AND STRATEGY BRANCH 1 (DCVAA1)
CONTENT MANAGEMENT AND STRATEGY BRANCH 2 (DCVAA2)
DIVISION OF DIGITAL EXPERIENCE AND INNOVATION (DCVAB)
DIGITAL EXPERIENCE AND INNOVATION BRANCH 1 (DCVAB1)
DIGITAL EXPERIENCE AND INNOVATION BRANCH 2 (DCVAB2)
OFFICE OF STRATEGIC AND CREATIVE COMMUNICATIONS (DCVB)
DIVISION OF MULTIMEDIA COMMUNICATIONS (DCVBA)
AUDIO VISUAL PRODUCTION BRANCH (DCVBA1)
GRAPHIC DESIGN BRANCH (DCVBA2)
DIVISION OF EDITORIAL AND CONTENT ENGAGEMENT (DCVBB)
SOCIAL MEDIA BRANCH (DCVBB1)
AGENCY INITIATIVES AND EDITORIAL BRANCH (DCVBB2)
INTERNAL COMMUNICATIONS AND ENGAGEMENT BRANCH (DCVBB3)
OFFICE OF PUBLIC ENGAGEMENT (DCVC)
DIVISION OF COMMISSIONER AND CENTER ENGAGEMENT (DCVCA)
COMMISSIONER ENGAGEMENT BRANCH (DCVCA1)
CENTER AND PROGRAM ENGAGEMENT BRANCH (DCVCA2)
DIVISION OF OUTREACH AND EDUCATION (DCVCB)
PATIENT AND CONSUMER OUTREACH BRANCH (DCVCB1)
PUBLIC EDUCATION BRANCH (DCVCB2)
OFFICE OF CENTER AND PROGRAM COMMUNICATIONS (DCVD)
DIVISION OF COMMUNICATIONS I (DCVDA)
COMMUNICATIONS BRANCH 1 (DCVDA1)
COMMUNICATIONS BRANCH 2 (DCVDA2)
COMMUNICATIONS BRANCH 3 (DCVDA3)
DIVISION OF COMMUNICATIONS II (DCVDB)
COMMUNICATIONS BRANCH 1 (DCVDB1)
COMMUNICATIONS BRANCH 2 (DCVDB2)
DIVISION OF COMMUNICATIONS III (DCVDC)
COMMUNICATIONS BRANCH 1 (DCVDC1)
COMMUNICATIONS BRANCH 2 (DCVDC2)
COMMUNICATIONS BRANCH 3 (DCVDC3)
II. Delegations of Authority
Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.
Secretary, Department of Health and Human Services.
Footnotes
3.
In light of the preliminary injunction in
New York
v.
Kennedy,
1:25cv196 (D.R.I.), the Center for Tobacco Products is not part of the proposed Reorganization.